DARK Classics in Chemical Neuroscience: Ibogaine

The extracted text presents a narrative, topical review rather than a systematic review or new experimental study. No explicit search strategy, inclusion criteria, database list, or formal methods for literature selection are reported in the extracted sections. Consequently, the provenance and comprehensiveness of the literature surveyed are not specified in the available text. Content is organised thematically: chemical synthesis and structure, manufacturing and regulatory status, drug metabolism and pharmacokinetics, structure–activity relationships, molecular pharmacology, adverse effects and dosing, and historical and translational significance. The review integrates primary preclinical data (rodent LD50s, self‑administration and microdialysis studies), human pharmacokinetic measurements (half‑lives, Cmax for ibogaine and noribogaine), in vitro receptor and transporter binding/functional data (affinity and IC50/Ki values against KOP, MOP, NMDA, DAT, SERT, nicotinic receptors, and hERG), and medicinal chemistry efforts that produced 18‑MC. Where numerical values are reported in figures or tables within the extracted text, those values are described in the pharmacokinetic and pharmacology sections of the review.

Chemical synthesis and manufacturing: The review summarises classical and more recent total syntheses of ibogaine, noting an original multistep route from the 1960s and a simplified 2012 synthesis with an overall yield of about 9.8% from a tropane‑containing intermediate. As a Schedule I compound in the U.S., ibogaine is restricted for research use; NIDA and commercial suppliers (e.g. Sigma‑Aldrich) provide material under licence. Legal status varies internationally, with prescription availability in Brazil and New Zealand but Schedule I or illegal status in several European countries. Metabolism and pharmacokinetics: Ibogaine is lipophilic and concentrates in adipose tissue in rats. The parent compound has a short half‑life (reported as ~2 h in rats and ~7 h in humans), while its primary active metabolite, noribogaine (12‑hydroxyibogaine), has a substantially longer half‑life in humans (reported range 27.6–49.7 h). Human liver microsome work implicates CYP2D6 (major) and CYP2C19 and CYP3A4 (minor) in demethylation to noribogaine. Reported whole blood Cmax after oral ibogaine doses of 500–800 mg were 700–1000 ng/mL. Plasma Cmax values for noribogaine after small oral doses (3–60 mg) ranged from ~5.2 ng/mL to ~116 ng/mL, with peak times at ~2–3 h. Rat brain concentrations of noribogaine after oral dosing indicate high brain penetration across a range of doses. Structure–activity relationships and analog development: The iboga alkaloid family comprises roughly 80 related structures. Toxicity concerns prompted medicinal chemistry focusing on the coronaridine scaffold and ultimately the development of 18‑methoxycoronaridine (18‑MC). 18‑MC retained efficacy in rodent models (reducing self‑administration of morphine and cocaine) while lacking the tremors and cerebellar neurotoxicity observed with ibogaine in some preclinical studies. Screening of 18‑MC analogs highlighted potent inhibition of the α3β4 nicotinic acetylcholine receptor as a common property linked to antiaddictive effects. Molecular pharmacology: Ibogaine and its metabolite noribogaine interact with many targets, typically with weak (micromolar) affinity, and no single primary receptor has been definitively identified. Key reported activities include: noribogaine partial agonism at κ opioid receptors (KOP) with KOP affinity ~0.61 μM and partial agonist efficacy (Emax ~72% of dynorphin A in one assay); ibogaine inhibition of NMDA receptor binding (IC50 ~5.2 μM in human caudate and 9.8 μM in cerebellum), which could relate to dissociative effects; binding to μ opioid receptors in the low‑ to sub‑micromolar range with noribogaine acting as a MOP partial agonist; and DAT and SERT inhibition with Ki values around 2 μM for DAT. Unusually, ibogaine is described as a noncompetitive DAT/SERT inhibitor that preferentially stabilises an inward‑facing transporter conformation and can act as a pharmacochaperone for misfolded transporters. Nicotinic receptor activity—particularly noncompetitive antagonism at α3β4 nACh receptors in the habenulo‑interpeduncular pathway—is emphasised as a likely contributor to anti‑craving effects. Functional inhibition IC50s for α3β4 are reported as ~0.95 μM for ibogaine, ~6.2 μM for noribogaine, and ~1.47 μM for 18‑MC, though binding assays yielded variable Kd/Ki values depending on method. Preclinical efficacy and behavioural findings: Animal studies beginning in the 1980s show that ibogaine and noribogaine reduce self‑administration of opiates, cocaine, nicotine and other reinforcers in rodents. A commonly cited model involved reduced morphine self‑administration after ibogaine pretreatment at doses above 10 mg/kg, with effects lasting weeks in some animals. Microdialysis studies reported that ibogaine pretreatment (40 mg/kg) decreased dopamine release in nucleus accumbens and prefrontal cortex in response to morphine, an effect that persisted beyond the parent drug’s elimination and consistent with active metabolite action. Toxicity and adverse effects: The review emphasises serious, dose‑dependent adverse effects that limit clinical use. Rodent LD50s are reported as 263 mg/kg for ibogaine and 630 mg/kg for noribogaine. Neurotoxicity has been observed in rodents, including Purkinje cell loss in the cerebellar vermis; mice and rats yielded divergent findings for this effect. In humans, nausea, ataxia and seizures have been reported at very high doses; in a Phase I study of noribogaine (36 males) headache and epistaxis were noted. Cardiotoxicity—specifically QTc interval prolongation—has been implicated in multiple fatalities and is mechanistically linked to hERG potassium channel inhibition (hERG IC50 ~4 μM in TSA‑201 cells). A review of 19 fatalities found pre‑existing cardiac disease contributed in a majority of cases with sufficient autopsy data. Reported subjective effects in recreational or ceremonial users include a multi‑phase experience lasting many hours to days, with a first phase of intense perceptual and cognitive phenomena lasting 4–8 h, a second phase of gradual decline over 8–20 h, and a return to normal consciousness over 1–3 days. Clinical translation and current status: Ibogaine was previously marketed in France but was removed due to adverse effects and later classified Schedule I in the U.S. Lotsof’s advocacy prompted preclinical and medicinal chemistry programmes that yielded 18‑MC, which retains antiaddictive efficacy in rodents without the tremors or cerebellar toxicity seen with ibogaine. The review notes that 18‑MC was being prepared for clinical trials in nicotine addiction at the time of writing.

Wasko and colleagues interpret the compiled evidence as portraying ibogaine as a ‘‘double‑edged sword’’: it has demonstrated antiaddictive effects in animal models and produced dramatic anecdotal reports in humans, yet it carries real risks of neurotoxicity, cardiotoxicity and death. The authors argue that noribogaine is an active metabolite likely responsible for prolonged behavioural effects, given its longer half‑life and brain penetration, and that multiple receptor interactions—rather than a single primary target—probably underlie the complex behavioural profile observed. In positioning these findings relative to prior research, the review highlights convergent data linking α3β4 nicotinic receptor inhibition, opioid receptor modulation, NMDA receptor antagonism and atypical DAT/SERT interactions to ibogaine’s anti‑reinforcement effects. The medicinal chemistry progression from ibogaine to coronaridine analogs, notably 18‑MC, is offered as a pathway to preserve therapeutic actions while reducing adverse effects; preclinical evidence supports this trajectory. The authors acknowledge key uncertainties and limitations evident in the literature: inconsistent preclinical neurotoxicity findings across species, the absence of a clearly dominant molecular target, variable assay results for receptor binding, and the lack of controlled, large‑scale clinical trials establishing safety and efficacy. They note that many fatal human cases involved pre‑existing cardiac disease, emphasising the need for cardiovascular screening and mechanistic study of hERG interactions. Regarding implications, the review suggests that continued medicinal chemistry to refine analogues, rigorous preclinical safety assessment, and carefully designed clinical trials are warranted. The authors also indicate that ibogaine analogs might be considered within the broader context of ‘‘psychedelic‑assisted therapy’’ for mood and anxiety disorders, drawing parallels to renewed clinical interest in other psychoactive compounds such as ketamine, psilocybin and MDMA. Nevertheless, the authors caution that any clinical development must reconcile potential benefits with well‑documented risks.

The authors conclude that ibogaine occupies a contested place in neuropharmacology: it shows promise for mitigating physical dependence and drug‑seeking in preclinical models but is accompanied by unpredictable and sometimes lethal toxicity in humans. They highlight 18‑MC as a promising analog that retains antiaddictive efficacy in animals without overt ibogaine‑like tremors or cerebellar toxicity at therapeutic doses, and note that 18‑MC was advancing toward clinical trials for smoking cessation. Wasko and colleagues favour a model in which ibogaine’s behavioural effects arise from simultaneous, multi‑receptor actions rather than a single undiscovered primary target. The review closes by reflecting on the historical trajectory—from Howard Lotsof’s anecdote to modern medicinal chemistry and NIH‑funded research—and suggests that a well‑tolerated structural analog may ultimately provide a viable pharmacotherapeutic for addiction and other CNS disorders.